Skip to main content

Table 1 Patient and Tumor characteristics

From: Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Nr.

Age Range

Symptoms

Duration of symptoms

Tumor location

in contact with CSF space

Contrast enhancement

Relevant patient history

1

70–79

general weakness, decline in overall health

few weeks

multifocal (left basal ganglia, right thalamus, hemispheres)

yes

Sparce, partial

no immunosuppression

2

40–49

general weakness, decline in overall health

few weeks

multifocal (basal ganglia, brainstem / medulla, cerebellar peduncles)

yes

Sparce, partial

HIV positive, previous EBV infection

3

60–69

gait disturbance, halluzinations

1,5 weeks

right basal ganglia

yes

Strong, homogenous

Melanoma of the scalp 4 years prior (excision only, no radiation/ chemo)

4

70–79

syncope, left hemiparesis, reduced alertness and arousal

2 weeks

bilateral basal ganglia, velum interpositum

yes

Strong, homogenous

no immunosuppression

5

70–79

right hemiparesis, reduced alertness, general weakness

3 weeks

left basal ganglia

yes

Strong, homogenous

no immunosuppression

6

70–79

right hand weakness, speech arrest

4 weeks

No tumor (contrast-enhancing meninges, left periventricular changes in T2 flair images)

yes

Strong (meninges)

systemtic B-cell lymphoma, full remission, no recurrence after 6 cycles of R-CHOP 8 years prior; rheumatoid arthritis (MTX-therapy)